Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital
's stock had its "buy" rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Saturday, MarketBeat reports. Other hedge funds have made changes to their positions in the company.
from Biotech News
0 Comments